AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
X4 Pharmaceuticals announced a strategic restructuring, reducing its workforce by 50% to achieve annualized cost savings of approximately $13 million. The company also appointed John Volpone as Chief Operating Officer, in addition to his current role as President. Dr. Adam Craig will have oversight over clinical development. The restructuring is aimed at sharpening operational focus and aligning resources with the long-term strategy to complete the 4WARD Phase 3 trial in patients with chronic neutropenia.
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet